Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026
Same author

Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome.

Obesity (Silver Spring, Md.)·2026
Same author

CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.

medRxiv : the preprint server for health sciences·2026
Same author

Do white matter hyperintensities account for the relationship between discrimination and memory?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The Genetic and Environmental Architecture of the Human Functional Connectome.

ArXiv·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Julie K Wisch1, Ziqiao Jiao2, Patrick J Lao3

  • 1Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

血pTau217可以预测唐氏综合征 (DS) 中的粉样蛋白阳性,并估计当粉样蛋白水平高时,对抗粉样蛋白治疗试验的资格时间. 然而,这项测试对于在DS患者中检测早期粉样蛋白阳性反应的敏感性有限.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经学 神经学
  • 生物标志物研究 生物标志物研究
  • 唐氏综合征研究 唐氏综合征研究

背景情况:

  • 唐氏综合征 (DS) 抗粉样蛋白治疗试验需要PET确认的粉样蛋白阳性才能将参与者纳入.
  • 疾病进展建模用于预测早期粉样蛋白水平的个体何时会满足试验标准.
  • 血pTau217是粉样质斑块存在的潜在生物标志物,但其在预测试验资格方面的实用性,特别是低粉样质水平,正在研究中.

研究的目的:

  • 评估血pTau217在检测DS的个体中粉样蛋白阳性的准确性.
  • 用血pTau217与粉胺PET进行疾病进展建模估计的时间到粉胺阳性的比较.
  • 评估血pTau217的灵敏度,以检测DS的早期粉样蛋白病理.

主要方法:

  • 包括来自ABC-DS研究的329名DS患者.
  • 使用了纵向粉样蛋白PET (PiB或AV45) 和血pTau217 (Lilly测定) 数据.
  • 采用ROC分析来确定粉样蛋白阳性的最佳pTau217值,并使用通用添加模型比较时间估计.

主要成果:

  • 对于粉样蛋白阳性 (15-30个百分位素) 确定了0.4778微克/毫升的最佳血pTau217截止值.
  • 血pTau217在较低的粉样蛋白水平 (<30CL) 上显示出高的可变性和较低的准确性 (MAE=5.2年, ρ=0.226).
  • 在30CL以上,血pTau217和PET估计的时间对阳性度的相关性很好 (MAE=3.5年, ρ=0.629).

结论:

  • 血pTau217有效地预测了粉样蛋白-PET阳性,并估计了DS患者的阳性时间,粉样蛋白负担>30CL.
  • 该试验在较低的粉样蛋白病理水平 (10-30 CL) 估计时间到阳性的有用性有限.
  • 特定的血pTau217测定可能缺乏早期检测粉样蛋白阳性的必要灵敏度.